Overview

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.
Phase:
PHASE2
Details
Lead Sponsor:
Kowa Research Institute, Inc.
Treatments:
(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid